Literature DB >> 19049846

Liberation of vessel adherent myeloperoxidase by enoxaparin improves endothelial function.

Tanja K Rudolph1, Volker Rudolph, Anna Witte, Anna Klinke, Katalin Szoecs, Denise Lau, Thomas Heitzer, Thomas Meinertz, Stephan Baldus.   

Abstract

BACKGROUND: Myeloperoxidase (MPO), a leukocyte-derived heme enzyme binds to the endothelium and depletes vascular nitric oxide (NO) bioavailability in animal models. Unfractionated heparins release vessel-bound MPO and increase endothelial NO bioavailability. Whether low molecular weight heparins also affect circulating MPO levels and NO dependent vasoreactivity however remains elusive. METHODS AND
RESULTS: In a randomized, double-blind, placebo-controlled trial patients with stable coronary artery disease received either 1 mg/kg enoxaparin or an equivalent volume of sodium chloride (NaCl) subcutaneously. Enoxaparin led to a significant improvement of FMD (5.51+/-0.53% vs. 6.55+/-0.58%, p=0.01) accompanied by a significant increase in plasma MPO levels (2.51 [IR: 2.04-3.62] ng/ml vs. 3.70 [IR: 2.80-5.50] ng/ml; p<0.001) whereas NaCl revealed neither a change in FMD (5.56+/-0.67% vs. 5.34+/-0.61%, p=ns) nor in plasma MPO levels (3.04 [IR: 2.22-4.67] ng/ml vs. 2.90 [IR: 1.95-4.32] ng/ml; p=ns). The extent of enoxaparin-induced MPO release and the improvement in endothelial function showed a good correlation (r=0.67, p<0.001). DISCUSSION: This study confirms the concept that heparins improve endothelial function, an established read-out of vascular NO bioavailability, by mobilizing vessel bound MPO. These data not only support the notion of extracoagulant, anti-inflammatory properties of heparins but reinforce the concept of MPO-dependent NO oxidation as a central mechanism for regulation of vascular tone in inflammatory vascular disease. (Eudra-CT number: 2005-006113-40). Copyright 2008 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19049846     DOI: 10.1016/j.ijcard.2008.10.035

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  10 in total

Review 1.  Low molecular weight heparin biosimilars: how much similarity for how much clinical benefit?

Authors:  Ludovic Drouet
Journal:  Target Oncol       Date:  2012-01-25       Impact factor: 4.493

2.  Platelet hyperaggregability in patients with atrial fibrillation. Evidence of a background proinflammatory milieu.

Authors:  Nathan E K Procter; Jocasta Ball; Doan T M Ngo; Yuliy Y Chirkov; Jeffrey S Isenberg; Elaine M Hylek; Simon Stewart; John D Horowitz
Journal:  Herz       Date:  2015-07-02       Impact factor: 1.443

Review 3.  HDL and endothelial protection.

Authors:  A Tran-Dinh; D Diallo; S Delbosc; L Maria Varela-Perez; Q B Dang; B Lapergue; E Burillo; J B Michel; A Levoye; J L Martin-Ventura; O Meilhac
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

Review 4.  Reactive Oxygen-Related Diseases: Therapeutic Targets and Emerging Clinical Indications.

Authors:  Ana I Casas; V Thao-Vi Dao; Andreas Daiber; Ghassan J Maghzal; Fabio Di Lisa; Nina Kaludercic; Sonia Leach; Antonio Cuadrado; Vincent Jaquet; Tamara Seredenina; Karl H Krause; Manuela G López; Roland Stocker; Pietro Ghezzi; Harald H H W Schmidt
Journal:  Antioxid Redox Signal       Date:  2015-11-10       Impact factor: 8.401

5.  Production of free radicals and oxygen consumption by primary equine endothelial cells during anoxia-reoxygenation.

Authors:  Geoffroy de Rebière de Pouyade; Alexandra Salciccia; Justine Ceusters; Ginette Deby-Dupont; Didier Serteyn; Ange Mouithys-Mickalad
Journal:  Open Biochem J       Date:  2011-11-24

6.  A rapid bioluminescence assay for measuring myeloperoxidase activity in human plasma.

Authors:  Reece J Goiffon; Sara C Martinez; David Piwnica-Worms
Journal:  Nat Commun       Date:  2015-02-10       Impact factor: 14.919

Review 7.  Anti-Inflammatory Effects of Heparin and Its Derivatives: A Systematic Review.

Authors:  Sarah Mousavi; Mandana Moradi; Tina Khorshidahmad; Maryam Motamedi
Journal:  Adv Pharmacol Sci       Date:  2015-05-12

8.  Activation and Inhibition of Human Matrix Metalloproteinase-9 (MMP9) by HOCl, Myeloperoxidase and Chloramines.

Authors:  Yihe Wang; Christine Y Chuang; Clare L Hawkins; Michael J Davies
Journal:  Antioxidants (Basel)       Date:  2022-08-20

9.  Myeloperoxidase-derived oxidants induce blood-brain barrier dysfunction in vitro and in vivo.

Authors:  Andreas Üllen; Evelin Singewald; Viktoria Konya; Günter Fauler; Helga Reicher; Christoph Nusshold; Astrid Hammer; Dagmar Kratky; Akos Heinemann; Peter Holzer; Ernst Malle; Wolfgang Sattler
Journal:  PLoS One       Date:  2013-05-14       Impact factor: 3.240

10.  Neutrophil-vascular interactions drive myeloperoxidase accumulation in the brain in Alzheimer's disease.

Authors:  Leon C D Smyth; Helen C Murray; Madison Hill; Eve van Leeuwen; Blake Highet; Nicholas J Magon; Mahyar Osanlouy; Sophie N Mathiesen; Bruce Mockett; Malvindar K Singh-Bains; Vanessa K Morris; Andrew N Clarkson; Maurice A Curtis; Wickliffe C Abraham; Stephanie M Hughes; Richard L M Faull; Anthony J Kettle; Mike Dragunow; Mark B Hampton
Journal:  Acta Neuropathol Commun       Date:  2022-03-24       Impact factor: 7.801

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.